Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Supplementary Figure 2 from Machine Learning and Real-World Data to Predict Lung Cancer Risk in Routine Care
0
Zitationen
6
Autoren
2025
Jahr
Abstract
<p>ROC and Calibration Plots for Temporal Validation. A, shows the area under the receiver operating characteristics curve for the main model indexed in 2013 and when it was applied to cohorts indexed in 2014, 2015, 2016, and 2017 as part of temporal validation in the Optum EHR dataset. B, shows calibration of the main model and the calibration for model applied to cohorts indexed in 2014, 2015, 2016, and 2017 in the Optum EHR dataset.</p>
Ähnliche Arbeiten
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.776 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.909 Zit.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 · 8.200 Zit.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 · 6.477 Zit.
Deep Convolutional Neural Networks for Computer-Aided Detection: CNN Architectures, Dataset Characteristics and Transfer Learning
2016 · 5.704 Zit.